138 related articles for article (PubMed ID: 29803207)
1. Telomere length and TERT abnormalities in pituitary adenomas.
Boresowicz J; Kober P; Rusetska N; Maksymowicz M; Goryca K; Kunicki J; Bonicki W; Bujko M
Neuro Endocrinol Lett; 2018 Mar; 39(1):49-55. PubMed ID: 29803207
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.
Miyake Y; Adachi JI; Suzuki T; Mishima K; Araki R; Mizuno R; Nishikawa R
J Neurooncol; 2019 Jan; 141(1):131-138. PubMed ID: 30392088
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
[TBL] [Abstract][Full Text] [Related]
4. N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma.
Vaitkiene P; Valiulyte I; Glebauskiene B; Liutkeviciene R
Diagn Pathol; 2017 Apr; 12(1):33. PubMed ID: 28390436
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profiling in nonfunctioning pituitary adenomas.
Kober P; Boresowicz J; Rusetska N; Maksymowicz M; Goryca K; Kunicki J; Bonicki W; Siedlecki JA; Bujko M
Mol Cell Endocrinol; 2018 Sep; 473():194-204. PubMed ID: 29410024
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
[TBL] [Abstract][Full Text] [Related]
9. hTERT promoter methylation in pituitary adenomas.
Köchling M; Ewelt C; Fürtjes G; Peetz-Dienhart S; Koos B; Hasselblatt M; Paulus W; Stummer W; Brokinkel B
Brain Tumor Pathol; 2016 Jan; 33(1):27-34. PubMed ID: 26390879
[TBL] [Abstract][Full Text] [Related]
10. Telomere length and telomerase expression in pituitary tumors.
Martins CS; Santana-Lemos BA; Saggioro FP; Neder L; Machado HR; Moreira AC; Calado RT; de Castro M
J Endocrinol Invest; 2015 Nov; 38(11):1243-6. PubMed ID: 25952298
[TBL] [Abstract][Full Text] [Related]
11. Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation.
Harada K; Arita K; Kurisu K; Tahara H
Surg Neurol; 2000 Mar; 53(3):267-74. PubMed ID: 10773260
[TBL] [Abstract][Full Text] [Related]
12. A pilot genome-scale profiling of DNA methylation in sporadic pituitary macroadenomas: association with tumor invasion and histopathological subtype.
Ling C; Pease M; Shi L; Punj V; Shiroishi MS; Commins D; Weisenberger DJ; Wang K; Zada G
PLoS One; 2014; 9(4):e96178. PubMed ID: 24781529
[TBL] [Abstract][Full Text] [Related]
13. Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma.
Jendrzejewski J; Tomsic J; Lozanski G; Labanowska J; He H; Liyanarachchi S; Nagy R; Ringel MD; Kloos RT; Heerema NA; de la Chapelle A
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1876-80. PubMed ID: 21900378
[TBL] [Abstract][Full Text] [Related]
14. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
[TBL] [Abstract][Full Text] [Related]
15. Telomere length alterations and ATRX/DAXX loss in pituitary adenomas.
Heaphy CM; Bi WL; Coy S; Davis C; Gallia GL; Santagata S; Rodriguez FJ
Mod Pathol; 2020 Aug; 33(8):1475-1481. PubMed ID: 32203094
[TBL] [Abstract][Full Text] [Related]
16. Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles.
Cheng S; Xie W; Miao Y; Guo J; Wang J; Li C; Zhang Y
J Transl Med; 2019 Dec; 17(1):407. PubMed ID: 31796052
[TBL] [Abstract][Full Text] [Related]
17. Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence.
Yoshino A; Katayama Y; Fukushima T; Watanabe T; Komine C; Yokoyama T; Kusama K; Moro I
J Neurooncol; 2003 Jun; 63(2):155-62. PubMed ID: 12825819
[TBL] [Abstract][Full Text] [Related]
18. TERT Expression in Pituitary Adenomas.
Can N; Çelik M; Bülbül BY; Süt N; Özyilmaz F; Aytürk S; Güldiken S; Sarikaş N; Puyan FÖ; Yalta TD; Kutlu AK
Turk Patoloji Derg; 2017; 33(2):103-111. PubMed ID: 28272680
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation of the TERT promoter and its impact on human cancer.
Lee DD; Komosa M; Nunes NM; Tabori U
Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
